Clinical Trial: A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07779031) titled 'A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT' on June 21.

Brief Summary: To explore the safety and efficacy of selinexor combined with azacitidine as post-transplant maintenance therapy for TP53-mutated AML/MDS.

Study Start Date: May 01, 2025

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukaemia (AML) MDS (Myelodysplastic Syndrome)

Intervention: DRUG: Azacitidine (AZA) Days 1 - 5

azacitidine 35mg/m2

DRUG: Selinexor

selinexor 20mg q2w

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: Liping Dou

Information pr...